PGx Study to Develop and Validate the Predictive Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy
This study has been completed.
Information provided by (Responsible Party):
Jae-Gook Shin, Inje University
First received: August 9, 2010
Last updated: May 30, 2013
Last verified: May 2013
To develop and validate the predictive warfarin dosing algorithm.
||Observational Model: Cohort
Time Perspective: Retrospective
||Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy in Korean Patients
Biospecimen Retention: Samples With DNA
Primary Outcome Measures:
- To Develop and Validate the Predictive Warfarin Dosing Algorithm [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Blood samples were taken from patients for genotyping about 8ml
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||April 2010 (Final data collection date for primary outcome measure)
This study aims to develop and validate the predictive warfarin dosing algorithm for personalized warfarin pharmacotherapy in Korean patients.
|Ages Eligible for Study:
||20 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
the patients taking warfarin
- the patients taking warfarin
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01178502
|Busan, Korea, Republic of, 614-735 |
No publications provided
||Jae-Gook Shin, Department of Pharmacology and Pharmacogenomics Research Center, Inje University
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 9, 2010
||May 30, 2013
||Korea: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 27, 2014
Heart Valve Diseases